![]() |
市场调查报告书
商品编码
1656901
预填充式注射器的全球市场:洞察,竞争情形,市场预测:2032年Prefilled Syringes - Market Insights, Competitive Landscape, and Market Forecast - 2032 |
预计 2024 年预充式註射器市场规模将达到 12,490,790,000 美元。预计预测期内(2025-2032 年),市场复合年增长率为 10.73%,到 2032 年将达到 279.9335 亿美元。由于慢性病的增加、生物製剂和生物相似药的使用增加以及自我给药的采用,全球预充式註射器市场正在成长。糖尿病和类风湿性关节炎等慢性疾病需要持续注射治疗,预充式註射器为患者提供了安全、方便的治疗方式。生物製剂和生物相似药用于治疗癌症和自体免疫疾病等复杂疾病,进一步推动了对易于使用的注射系统的需求。此外,在家中自行给药的转变提供了额外的便利,从而增加了对预充式註射器的整体需求。综合起来,这些因素使得预充式註射器在 2025 年至 2032 年的预测期内将呈现强劲的成长轨迹。
根据世界心臟组织(WHO)提供的最新数据(2023年),全球约有5.28亿人患有骨关节炎。
此外,根据健康指标与评估研究所 (2023) 提供的最新数据,预计到 2050 年将有约 10 亿人患有骨关节炎,其中膝盖和臀部是最常见的患处。具体而言,膝关节骨关节炎预计增加74.9%,腕关节骨关节炎预计将增加48.6%,髋关节骨关节炎预计增加78.6%,肘部和肩部等其他部位骨关节炎预计增加95.1%。
患有骨关节炎的患者通常需要注射玻尿酸或皮质类固醇来缓解疼痛并改善关节活动性。预充式註射器为在诊所和家中进行这些治疗提供了一种方便且无菌的方式,从而促进了全球预充式註射器市场的发展。例如,由赛诺菲旗下子公司 Genzyme Corporation 生产的 Synvisc-One® 是一种预充式註射器,有助于润滑和缓衝膝关节,缓解骨关节炎疼痛长达六个月。
此外,世界卫生组织 (WHO) (2023) 的最新数据报告称,全球有超过 180 万人患有多发性硬化症。多发性硬化症导致免疫系统错误地攻击大脑和脊髓,影响许多方面的功能,包括认知、情绪、运动、感觉和视觉。预充式註射器对于治疗这种疾病至关重要,因为它们提供了一种即用型、准确且易于使用的输送系统,可简化给药、减少用药错误并提高患者对治疗方案的依从性。例如,AVONEX 是一种每週一次的复发性多发性硬化症治疗药物,采用 30mcg 肌肉注射预充式自註射器形式。
此外,单株抗体、生长因子和疫苗等生物製剂对于治疗癌症和自体免疫疾病等慢性疾病至关重要。预充式註射器透过注射给药,提供了一种方便且精确的给药方法。此外,生物相似药和生物相似药的兴起进一步推动了对预充式註射器的需求,提供了更便宜的治疗选择。
本报告提供全球预填充式注射器市场相关调查,提供市场概要,以及各产品类型,不同材料,各类型,各流通管道,各地区趋势,及加入此市场的主要企业简介等资讯。
Prefilled Syringes Market by Product Type (Staked Needle System, Luer Cone System, and Luer Lock System), Material (Glass and Plastic), Type (With Needle and Without Needle), Distribution Channel (Hospital & Retail Pharmacies and Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the increasing prevalence of chronic diseases, increase impact of biologics and biosimilar on prefilled syringes, increase adoption of self-administration across the globe.
The prefilled syringes market was valued at USD 12,490.79 million in 2024, growing at a CAGR of 10.73% during the forecast period from 2025 to 2032 to reach USD 27,993.35 million by 2032. The global prefilled syringes market is growing due to the rise in chronic diseases, increased use of biologics and biosimilars, and the adoption of self-administration. Chronic conditions like diabetes and rheumatoid arthritis require ongoing injectable treatments, and prefilled syringes offer patients a safe, convenient way to manage their care. The use of biologics and biosimilars for complex conditions like cancer and autoimmune diseases has further driven demand for user-friendly injection systems. Additionally, the shift towards self-administration at home enhances convenience and boosts the overall demand for prefilled syringes. Collectively, these factors foster a robust growth trajectory for the prefilled syringes during the forecast period from 2025 to 2032.
Prefilled Syringes Market Dynamics:
According to the recent data provided by the World Heart Organization (2023), about 528 million people globally were living with osteoarthritis.
Additionally, according to the recent data provided by the Institute for Health Metrics and Evaluation (2023), by 2050, nearly one billion people are projected to have osteoarthritis, with the most common areas affected being the knees and hips. Specifically, osteoarthritis of the knee is expected to increase by 74.9%, osteoarthritis of the hand by 48.6%, osteoarthritis of the hip by 78.6%, and osteoarthritis in other areas, such as the elbow and shoulder, by 95.1%.
Patients with osteoarthritis often need hyaluronic acid or corticosteroid injections for pain relief and joint mobility. Prefilled syringes provide a convenient and sterile method for administering these treatments in clinical and home settings, thus boosting the global prefilled syringe market. For example, Synvisc-One(R) manufactured by Genzyme Corporation, which is a subsidiary of Sanofi is a prefilled syringe that helps lubricate and cushion the knee joint, offering relief from osteoarthritis pain for up to six months.
Additionally, as per recent data from the World Health Organization (2023), it was reported that over 1.8 million people worldwide were affected by multiple sclerosis. Multiple sclerosis impacted various functions, including cognitive, emotional, motor, sensory, and visual abilities, as the immune system mistakenly attacked the brain and spinal cord. Prefilled syringes were crucial for managing the condition, as they simplified dosing, reduced medication errors, and enhanced patient adherence to treatment regimens by offering a ready-to-use, accurate, and user-friendly delivery system. For instance, AVONEX is a once-weekly treatment for relapsing multiple sclerosis, provided as a 30 mcg intramuscular prefilled self-syringe.
Moreover, Biologics, including monoclonal antibodies, growth factors, and vaccines, are crucial for treating chronic conditions like cancer and autoimmune diseases. Administered via injection, prefilled syringes offer a convenient and accurate delivery method. Additionally, the rise of biosimilar generic versions of biologics has further propelled the demand for prefilled syringes, providing a more affordable treatment option.
For instance, in July 2024, Sandoz Group AG, a global leader in generic and biosimilar medicines, announced that the U.S. Food and Drug Administration (FDA) approved its biosimilar Pyzchiva(R)* (ustekinumab-ttwe) in 45 mg/0.5 mL and 90 mg/mL pre-filled syringes for subcutaneous injection, as well as a 130 mg/26 mL (5 mg/mL) single-dose vial for intravenous infusion.
Thus, the factors mentioned above are expected to boost the overall market of prefilled syringes across the globe during the forecast period from 2025 to 2032.
However, increasing product recalls and failures due to safety issues and the availability of alternative products may hinder the future market of prefilled syringes across the globe during the forecasted period.
Prefilled Syringes Market Segment Analysis:
Prefilled Syringes Market by Product Type (Staked Needle System, Luer Cone System, and Luer Lock System), Material (Glass and Plastic), Type (With Needle and Without Needle), Distribution Channel (Hospital & Retail Pharmacies and Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
The staked needle system category in the prefilled syringes market is estimated to dominate the market with a market share of 68.37% in 2024. The adoption of staked needle systems is significantly boosting the overall market of prefilled syringes by addressing key challenges in drug delivery and enhancing the usability, safety, and efficiency of injectable therapies. A staked needle system integrates the needle directly into the syringe barrel, eliminating the need for additional assembly, such as attaching a separate needle. This design simplifies the injection process, reduces preparation time, and minimizes the risk of needle-related complications, such as detachment or improper attachment, making it highly preferred in both clinical and self-administration settings.
One of the major drivers of the staked needle system's impact is its contribution to patient safety. The fixed-needle design reduces the risk of needle-stick injuries, which is a critical concern for healthcare professionals, especially in high-pressure environments like hospitals and emergency care. Additionally, the reduced dead space in staked needle systems ensures precise dosing and minimizes medication waste, which is particularly advantageous for high-cost biologics, vaccines, and specialty drugs. This attribute makes staked needle systems an ideal choice for administering small-volume, high-potency medications, aligning with the growing demand for precision medicine. The integration of staked needle systems into advanced prefilled syringes, such as autoinjectors and pen injectors, further boosts their appeal in the rapidly growing self-injection device market.
Pharmaceutical companies are increasingly adopting staked needle systems for their prefilled syringes due to their compatibility with a wide range of drugs, including biologics and biosimilars, which are gaining traction globally. The design ensures the sterility and integrity of the drug product, reducing the likelihood of contamination or degradation. Furthermore, staked needle systems are well-suited for high-speed, automated manufacturing processes, enabling efficient large-scale production while maintaining consistent quality, which aligns with the rising demand for prefilled syringes worldwide.
Thus, the factors mentioned above are expected to boost the segment thereby boosting the overall market of prefilled syringes across the globe.
North America is expected to dominate the overall prefilled syringes market:
Among all regions, North America is estimated to hold the largest share of 34% in the global prefilled syringes market in 2024, growing at a CAGR of 11.02% during the forecast period from 2025 to 2032. This can be attributed to the rising prevalence of various chronic disorders such as diabetes, autoimmune diseases, and others. The use of biologics and biosimilars for complex conditions like cancer and autoimmune diseases has further driven demand for user-friendly injection systems. Additionally, the increase in strategic activities among the key market players is further boosting the overall market of prefilled syringes across the region.
According to data provided by the Centers for Disease Control and Prevention (CDC) in 2023, it was estimated that around 53.2 million people (21.2%), had been diagnosed with arthritis and rheumatoid arthritis in the United States, between 2019 to 2021.
Additionally, as per the data provided by the Centers for Disease Control and Prevention 2024, it was stated that around 38.4 million, accounting for 11.6% of the US population was suffering from diabetes, in 2021. Chronic diseases like diabetes and rheumatoid arthritis require continuous treatment over the long term. Patients need regular injections to manage their conditions, often for the rest of their lives. Prefilled syringes make these daily treatments easier, and more accurate, and allow easy self-administration of medications at home.
Furthermore, the well-established patient care system along with high awareness among patients and caregivers regarding different types of prefilled syringes is further expected to propel the United States prefilled syringes market growth.
Moreover, the increasing use of prefilled syringes highlights the rapid adoption of technologically advanced solutions, which is expected to drive market growth. For instance, in March 2024, Mallinckrodt plc. announced that the U.S. FDA approved the Acthar(R) Gel (repository corticotropin injection) Single-Dose SelfJect(TM) Injector, a new delivery device for Acthar Gel for patients with chronic and acute inflammatory and autoimmune conditions. The SelfJect was designed to allow patients greater control over their medication administration.
Thus, the above-mentioned factors are expected to escalate the market of prefilled syringes in the region.
Prefilled Syringes Market Key Players:
Some of the key market players operating in the Prefilled Syringes market include BD, Nipro Corporation, Taisei Kako Co., Ltd., Terumo Corporation, SCHOTT Pharma AG & Co. KGaA, Gerresheimer AG, Johnson and Johnson Services, Inc., Dali Medical Devices, Stevanato Groupand, Credence MedSystems, Inc., Baxter, MAEDA INDUSTRY Co., Ltd., MedXL, Inc., Sanofi, Sandoz AG, Pfizer Inc., B. Braun Melsungen AG, Novartis AG, Fresenius SE & Co. KGaA, Cardinal Health, and others.
Recent Developmental Activities in the Prefilled Syringes Market:
Key Takeaways From the Prefilled Syringes Market Report Study
Target Audience Who Can be Benefited From This Prefilled Syringes Market Report Study
Frequently Asked Questions for the Prefilled Syringes Market: